Capture Real-World Evidence

Tap into consented,
recontactable cohorts

From preclinical development to post-approval marketing, leverage Inspire’s unique mix of data assets and advanced analytic capabilities to capture deeper real-world evidence.

Our approach

Every day, patients are generating vast amounts of data. We combine both patient experience and medical data from millions of Inspire patients to empower real-world evidence generation for numerous diseases.

Filling evidence gaps

We help HEOR and Medical Affairs teams answer questions about how patients adhere to prescribed treatment regimens and reasons they stop, compare treatment effectiveness, identify unmet patient needs, and more.

Inspire’s patient cohorts

Inspire’s Real-World Evidence Platform is powered by existing consented and recontactable cohorts from the Inspire patient community. This includes over 3,000 conditions across rare disease, chronic disease and cancer.  

1 Million+ oncology/solid tumor
Lung, Breast, Cervical, Thyroid, Ovarian, Bladder, Brain, Prostate, Colorectal, Liver, Head & Neck, Pancreatic, Melanoma, Kidney, Gastric, Soft Tissue Sarcoma, PNET

800K rare disease
Ehlers Danlos, Neurofibromatosis, Interstitial Cystits, Nephrotic  / FSGS, Mast Cell Disease, Charcot-Marie Tooth, Tuberous Sclerosis, Wilson’s Disease, Sickle Cell Anemia, Leukodystrophy, Amyloidosis, Cystic Fibrosis, Cushing’s Disease

850 Autoimmune conditions
Psoriasis, Fibromyalgia, Eczema, Rheumatoid Arthritis, Scleroderma (SS), Psoriatic Arthritis, Lupus, Crohn’s Disease, Ulcerative Colitis, Celiac Disease, Sjogren’s

100K Oncology/Hematology
Lymphoma, Leukemia, Non-Hodgkins Lymph, Multiple Myeloma, Chr. Lymph. Leukemia (CLL), Acute Myeloid Leukemia (AML), Chr. Myeloid Leukemia (CML), Myelofibrosis

Inspire Virtual Registry

Get instant access to a condition or product-specific virtual registry built on Inspire’s robust member data. Our virtual registries combine existing and prospectively collected PRO, EHR and other target datasets as needed.

Some examples of our work

Pfizer had been unable for years to find patients to test a hypothesis linking rare genetic drivers to increasing cancer survivability. Inspire was able to identify and recruit more than 120 patients for genetic sequencing.

Inspire helped shed light on disease burden and unmet needs for patients with 2 rare neuromuscular conditions.

Inspire researchers accurately identified adverse drug reactions in cancer patients by using Inspire data, 7 months ahead of FDA reporting of the same adverse reactions.

Our research

See how we’ve helped leading biopharmaceutical companies tackle real-world data and evidence challenges. View Inspire’s latest publications.

Featured projects

Social media posts reveal the true impact of multiple myeloma on patients and caregivers

Benefits of linking social media posts to glean richer medical insights

Analysis of online community posts reveals impact of statins on memory

Contact us to learn more

"*" indicates required fields

This field is for validation purposes and should be left unchanged.